

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: Hiroaki ITO et al.  
Title: A PREVENTIVE OR THERAPEUTIC AGENT FOR  
INFLAMMATORY BOWEL DISEASE COMPRISING IL-6  
ANTAGONIST AS AN ACTIVE INGREDIENT  
Appl. No.: 10/677,227  
Filing Date: 10/3/2003  
Examiner: Prema Maria MERTZ  
Art Unit: 1646  
Conf. No.: 8597

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(d), before payment of the issue fee.

**RELEVANCE OF EACH DOCUMENT**

All of the documents are in English. Documents F1 and F2 were cited in an Office Action in the counterpart Chilean application. Documents F4 and F5 were cited in a communication in Opposition proceedings against corresponding EP 99907951, a copy of which communication is submitted as Document F3.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

**STATEMENT**

The undersigned hereby states in accordance with 37 CFR §1.97(e)(1) that each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to filing of this Statement.

**FEE**

Fees in the amount of \$180.00 to cover the fee associated with an information disclosure statement under 37 CFR §1.97(d) are being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this submission under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741.

Respectfully submitted,

Date June 4, 2010

By 

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4726  
Facsimile: (202) 672-5399

Simon J. Elliott  
Attorney for Applicant  
Registration No. 54,083